🔴 Critical Risk

DRMA: Dermata Therapeutics, Inc.
Dilution Risk Score 90/100

📅 Updated March 2026 📊 Real-time EDGAR data ✍️ DilutionWatch Analysis

Dermata Therapeutics, Inc. (DRMA) carries a Critical dilution risk score of 90 out of 100 based on DilutionWatch's real-time analysis of SEC EDGAR filings. Contributing factors include 7 dilutive SEC filings in the past 12 months.

90/100 Dilution Risk Score

9.0 months Est. Cash Runway

39% Warrant Overhang

7 Dilutive Filings (12mo)

Why DRMA Has a Critical Dilution Risk Score

DilutionWatch scores every ticker on a 0–100 scale by analyzing five components: cash runway, warrant overhang, convertible securities, active shelf/ATM capacity, and historical filing patterns. A score of 90 means DRMA is in the highest-risk category across multiple dimensions simultaneously.

Cash runway: Estimated at 9.0 months — moderate, but ongoing losses will require additional capital
Warrant overhang: Outstanding warrants represent 39% of current shares outstanding — significant potential dilution if exercised at or near current prices
Convertible securities: Convertible notes/instruments represent 61% of current shares — material dilution risk if converted
Filing pattern: 7 dilutive filings in the past 12 months (last: 2026-01-29), indicating a pattern of repeat capital raises

🔴 Risk Assessment

A dilution score of 90/100 places DRMA in the top tier of dilution risk across DilutionWatch's 10,000+ ticker universe. Investors should review all SEC filings carefully before taking or holding a position. This is not financial advice.

Recent SEC Filing History for DRMA

The following dilutive filings have been detected for DRMA in the past 12 months via DilutionWatch's real-time EDGAR monitoring:

Last filed2026-01-29 — most recent dilution-related filing detected

Count7 dilutive filings in the trailing 12 months

MonitorReal-time alerts available on DilutionWatch — free tier includes DRMA

How to Monitor DRMA for Dilution Alerts

DilutionWatch polls SEC EDGAR every 60 seconds. When Dermata Therapeutics, Inc. files an S-3, 424B, 8-K financing disclosure, or any of 25 tracked filing types, you receive an alert before the stock reprices. This is the same monitoring capability that institutional traders use — available to retail investors through DilutionWatch's free tier.

Get Real-Time DRMA Dilution Alerts

Free to start. Add DRMA to your watchlist and get alerted the moment a new SEC filing appears — before the market reacts.

Track DRMA Free →